Featured Story | By Eric Sagonowsky Sanofi has been no stranger to the biopharma dealmaking circuit under CEO Paul Hudson, and last year it inked a handful of biotech buyouts for mRNA, an FDA-approved transplant med and more. Now, when asked about the company's business development plans going forward, Sanofi's CFO said the company thinks it can build an industry-leading immunology franchise. read more |
| |
|---|
|
Top Stories By Paige Minemyer "We were obviously seeing positive signs across all of our businesses, all of our businesses did very well," CFO Shawn Guertin said. "Retail, in particular, has outperformed in the fourth quarter." read more By Kyle LaHucik It's been more than two years since a substantial update has been provided on bluebird bio and Bristol Myers Squibb's partnership on a multiple myeloma CAR-T. Now, development of the treatment is being shut down. read more By Fraiser Kansteiner Near term, Amgen is gearing up for a major biosimilar debut in Amjevita, which references its immunology powerhouse Humira. That copycat is poised to launch in the U.S. on Jan. 31, 2023. After that, Amgen expects to be among the vanguard of biosimilar launches to Stelara, Eylea and Soliris. read more By Conor Hale The new G7 wearable glucose sensor "very comfortably meets" the FDA’s accuracy requirements, according to Dexcom CEO Kevin Sayer. read more By Kyle LaHucik Sana Biotechnology, with a 2021 IPO under its wing, wants to get into the clinic next year to treat multiple myeloma, so it's linking arms with IASO Biotherapeutics and Innovent Biologics. The Seattle biotech will dole out up to $204 million in biobucks for nonexclusive access to the duo's CAR construct for use in in vivo gene therapies and ex vivo cell therapies. read more By Heather Landi,Paige Minemyer,Dave Muoio,Robert King,Rebecca Torrence,Anastassia Gliadkovskaya Executives from Mass General Brigham say that the integrated health system is viewing the bulk of its growth investments in two buckets separate from the traditional approach of horizontal acquisitions or integration. read more By Conor Hale In a presentation at the J.P. Morgan Healthcare Conference, CEO Francis deSouza said the accelerating use of genomics in healthcare pushed Illumina to about $4.517 billion in 2021 revenue, an increase of 39% over last year. read more By Annalee Armstrong Andrew Obenshain officially took over as bluebird bio’s CEO when the company split into two back in November. But there’s one item from his prior desk that's still on his mind: the removal of Zynteglo from the European market. read more By Heather Landi Aledade, the startup company that is working to reshape primary care, notched its first tuck-in acquisition by scooping up Iris Healthcare, the company announced Tuesday. read more By Andrea Park Once as improbable an idea as seeing pigs fly, the xenotransplantation of organs from animals to humans is becoming an increasingly viable option as the science of genetic editing improves and organ donor waitlists lengthen. read more By Andrea Park Less than a year after debuting its Wirion embolic protection system, Cardiovascular Systems is recalling all of the devices manufactured and distributed between January and November of last year. read more By Ben Adams,Annalee Armstrong,Kyle LaHucik,Conor Hale All you need to know from the second day of the J.P. Morgan Healthcare Conference. read more |
|
